Barclays PLC (BCS)
After hours:
| Previous close | 11.75 |
| Open | 11.89 |
| Bid | 11.97 x 4000 |
| Ask | 11.98 x 3200 |
| Day's range | 11.85 - 12.01 |
| 52-week range | 6.23 - 12.12 |
| Volume | |
| Avg. volume | 11,229,840 |
| Market cap | 44.286B |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | 8.94 |
| EPS (TTM) | 1.34 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | 0.35 (2.95%) |
| Ex-dividend date | 29 Feb 2024 |
| 1y target est | 11.62 |
BloombergMankind Taps Barclays, Deutsche Bank to Fund $1.6 Billion Buy
(Bloomberg) -- Mankind Pharma Ltd. has picked Barclays Plc and Deutsche Bank AG to help arrange financing for its proposed 138 billion rupees ($1.6 billion) acquisition of Bharat Serums & Vaccines Ltd., according to people familiar with the matter.Most Read from BloombergTrump Risks Losing Voters He Needs With Loaded Attacks on HarrisParis Sticks to Olympics Opening Event Plans After Rail SabotageFed’s Favored Price Gauge Rises at Mild Pace, Spending Holds UpHarris Just Showed Why Trump Is So Af
Yahoo Finance UKBest UK savings accounts offering above inflation rates
See the best savings accounts to find a top-rated deal that works for you.
ReutersExclusive-Barclays reaps hedge fund riches in battle of the prime brokers
Barclays is winning business from its top Wall Street rivals in prime brokerage, a lucrative investment banking battleground where lenders are battling to serve hedge funds in an array of increasingly complex trades. The British bank has risen to fifth in the revenue table for prime broking for the year to the end of June, from around seventh five years ago, according to data seen by Reuters from research firm BCG Expand. A second provider, who did not want to be named discussing sensitive client data, confirmed the fifth place ranking.
